Skip Navigation Archive: U.S. Department of Health and Human Services U.S. Department of Health and Human Services
Archive: Agency for Healthcare Research Quality
Archival print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to for current information.

  • Publication # 13-RA009

Combination chemotherapy increases the risk for adverse events in elderly patients with colorectal cancer

Elderly Health/Long-Term Care

About 70 percent of colorectal cancers (CRC) develops in patients over the age of 65. Treatment options in these elderly patients include the use of single-agent or combination-based chemotherapies. However, elderly patients are particularly vulnerable to side effects, especially when drugs are used in combination, according to a new study. 

Researchers used a large population-based database with Medicare-linked information to identify 46,692 patients 65 years of age or older with CRC. Medicare data were used to determine what types of chemotherapy, if any, these patients received. There were 5 categories of patients: no intravenous chemotherapy (77.4 percent), fluorouracil (5-FU) alone (11.7 percent), oxaliplatin-based (4.9 percent), bevacizumab-containing chemotherapy (2.8 percent), and other chemotherapy (3.2 percent). Adverse events and toxicities, including abnormal laboratory profiles, were identified. 

Patients who received chemotherapy tended to be younger, had more advanced cancers, and were more likely to be married compared to patients who did not get chemotherapy. All patients, whether receiving chemotherapy or not, had a high incidence of symptoms and laboratory test abnormalities, which increased after patients began receiving chemotherapy. Compared to patients on 5-FU alone, those on an oxaliplatin-based regimen had higher rates of adverse events, including nausea and neuropathy. Those 70 years of age and older were more likely to experience certain adverse events such as infection, anemia, delirium, and heart disease. 

The study was supported in part by AHRQ (HS16743). See "comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer," by Putao Cen, M.D., Chih-Chin Liu, Ph.D., and Xianglin L. Du, M.B., M.S., Ph.D., in the June 2012 Annals of Oncology 23(6), pp. 1503-1511.


Page last reviewed June 2013
Internet Citation: Combination chemotherapy increases the risk for adverse events in elderly patients with colorectal cancer: Elderly Health/Long-Term Care. June 2013. Agency for Healthcare Research and Quality, Rockville, MD.


The information on this page is archived and provided for reference purposes only.


AHRQ Advancing Excellence in Health Care